查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1458410

全球伴隨診斷市場：依產品、技術、應用、最終用戶、地區、機會、預測，2017-2031 年

Companion Diagnostics Market Assessment, By Product, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 228 Pages | 商品交期: 3-5個工作天內

價格

伴隨診斷市場規模預計將從 2023 年的 71 億美元成長到 2031 年的 154.8 億美元，2024-2031 年預測期間的複合年增長率為 10.23%。 伴隨診斷市場預計將在個人化醫療需求不斷增長、癌症患者數量不斷增加以及診斷和治療技術進步等驅動力的影響下增長。 隨著對客製化醫療設施和個人化健康解決方案的需求增加，伴隨診斷市場預計將呈指數級增長。 癌症發生率的上升正在推動市場對伴隨診斷產品的需求，以滿足市場對伴隨診斷產品不斷增長的需求。 製造商和創新者不斷致力於技術進步並利用多種診斷技術來開發高品質的產品。 此外，美國FDA、CDSCO等監管機構和其他活動機構正積極考慮批准各種開發產品。

伴隨診斷方法在提供個人化醫療方面發揮著極其重要的作用。 伴隨診斷測試對於揭示見解以更好地瞭解導致特定疾病的基因、生物標記和其他生物醫學因素非常有用。 伴隨診斷使醫療保健提供者能夠確定患者是否會對治療產生反應，進一步確保針對性治療的安全性和有效性，並消除因反覆試驗方法而浪費的時間，從而可以為患者選擇最合適的治療方法。 大公司也積極參與伴隨診斷的創新。

癌症盛行率的上升預計將顯著增加對伴隨診斷和產品的需求。 伴隨診斷90%以上的產品類型主要針對各種癌症，這增加了各種癌症適應症的市場佔有率。 非小細胞肺癌 (NSCLC)、乳癌和大腸癌是 FDA 批准並提供伴隨診斷的最常見癌症類型。 由於癌症的盛行率預計在未來幾年將急劇增加，製造商正在積極開發產品，以滿足伴隨診斷不斷增長的市場需求。

本報告研究了全球伴隨診斷市場，並提供了市場概述，包括依產品、技術、應用、最終用戶、地區和參與該市場的公司的概況劃分的趨勢。

目錄

第一章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章 2017-2031 年全球伴隨診斷市場前景

  • 市場規模與預測
  • 依產品
  • 依技術
  • 依用途
  • 依最終用戶
  • 依地區
  • 各公司的市佔率 (%)，2023 年

第 5 章 2017-2031 年全球伴隨診斷市場前景（依地區）

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章 2023 年市場規劃

第七章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

第 9 章監理架構與創新

第十章主要參會企業狀況

第11章價格分析

第 12 章案例研究

第 13 章主要進入者展望

  • Roche Molecular Systems Inc.
  • Dako Inc.
  • Qiagen Ltd.
  • bioMerieux Inc.
  • Ventana Medical Systems Inc.
  • Abbott Molecular Inc.
  • Myriad Genetics Inc.
  • Biogenex Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Leica Biosystems Nussloch GmbH

第 14 章策略建議

第十五章查詢及免責聲明

Product Code: MX11207

Global companion diagnostics market is projected to witness a CAGR of 10.23% during the forecast period 2024-2031F, growing from USD 7.1 billion in 2023 to USD 15.48 billion in 2031F. The companion diagnostics market is anticipated to grow under the influence of driving forces such as the growing demand for personalized medicine, the growing prevalence of cancer cases, and technological advances in diagnostics and therapeutics. As the demand for tailored medical facilities and personalized health solutions is rising, the market for companion diagnostics is expected to expand exponentially. The rising incidence of cancer cases boosts the demand for companion diagnostics products in the market to cater to the growing market demand for such products. Manufacturers and innovators are constantly involved in technical advances and utilization of several diagnostic techniques to develop high-quality products. In addition, regulatory agencies such as the United States FDA, CDSCO, and others are actively looking after the approvals of various developed products.

For instance, in December 2023, the United States FDA approved 173 products of companion diagnostic devices (in vitro and imaging tools). These products are mainly approved for the United States market to perform companion diagnostics tests.

Growing Demand for Personalized Medicine

Companion diagnostics methods play a pivotal role in providing personalized medicine. A companion diagnostic test crucially helps to unlock insights for a better understanding of the specific disease-causing genes, biomarkers, and other biomedical factors. Companion diagnostics enable healthcare providers to determine whether the patient responds to treatment or not, further ensuring the safety and efficacy of targeted therapies and simultaneous selection of the finest treatment for that patient without wasting time with trial-and-error method. The key players are also actively involved in driving innovation in companion diagnostics.

For instance, in September 2023, Cell Signaling Technology (CST), partnered with Leica Biosystems, to develop companion diagnostics assays by utilizing the CST's extensive best-in-class antibodies portfolio. Leica is a global leader in providing the translation of pre-clinical research into companion diagnostics tests, further enabling pharmaceutical partners to develop and commercialize innovative diagnostic solutions. Cell Signaling Technology is a life science technology company and a leading provider of antibodies, kits, and services.

Growing Prevalence of Cancer

The growing prevalence of cancer cases is anticipated to significantly increase the demand for companion diagnostics methods and products. More than 90% of the market products addressing companion diagnostics are mainly indicated for various types of cancers, which further contributes to the larger market share of various types of cancer indications. Non-small Cell Lung Cancer (NSCLC), breast cancer, and colorectal cancer are some of the most common types of cancers for which the companion diagnostics products are FDA-approved and marketed. Manufacturers are actively involved in product development to cater to the market requirement to address the rising demand for such products as the prevalence of cancer is anticipated to increase drastically in the upcoming years.

For instance, in October 2023, Foundation Medicine Inc. announced that it had received United States FDA approval for FoundationOneCDx and FoundationOneLiquidCDx to be used as companion diagnostics with BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) of Pfizer for the treatment of adult metastatic non-small cell lung cancer (NSCLC) patients having BRAF V600E mutation.

Dominance of Real-time PCR Segment

The real-time PCR segment is anticipated to contribute to the largest market share in the market due to its speed, sensitivity, and accuracy in the detection and quantification of genetic material, which is crucial for detecting the therapeutic efficacy of drugs. Manufacturers are actively involved in product development and collaborative approaches to harness the resources at optimum levels to enhance market growth.

For instance, in October 2023, QIAGEN and Myriad Genetics announced a collaboration agreement for the development of companion diagnostic tests in the field of cancer. The collaboration aims to deliver curative products and services for pharmaceutical companies, further, enabling the development of commercial proprietary cancer diagnostics tests for the United States market, and subsequently providing companion diagnostic test kits for the global market. Through this collaboration, Myriad will leverage its robust commercial infrastructure for clinical sample testing and CLIA-certified, CAP-accredited lab platform, and assay development expertise while QIAGEN will contribute through its Sample to Insight solutions which include its PCR offerings, sample preparation, QIAseq next-generation sequencing technologies, and the QIAGEN Digital Insights portfolio of bioinformatics. The collaboration also focuses on the combined FDA and worldwide regulatory expertise of both organizations.

Hospitals are Chief End-users

The hospital end-user segment is anticipated to secure the largest market share in the global companion diagnostics market because the fundamental of companion diagnostics and therapy administration is mainly done in hospital settings. Most of the companion diagnostics products are consumed in hospital settings during the treatment of cancer patients at these setups. Hospitals are collaborating with manufacturers to facilitate the patients to leverage the potential of companion diagnostics for enhancing revenue.

For instance, in December 2023, ARUP Laboratories and Medicover collaborated to facilitate the market access of a new companion diagnostic, and a new gene therapy in the European Union (EU). ARUP Laboratories, developed AAV5 DetectCDx, a companion diagnostic in collaboration with BioMarin Pharmaceutical Inc. The test helps in the selection of adult patients suffering from severe hemophilia A who can get treatment with BioMarin's new gene therapy, ROCTAVIAN (valoctocogene roxaparvovec-rvox). Medicover is the provider of diagnostics and hospital services in the EU and thus contributes largely to the market expansion of AAV5 DetectCDx and ROCTAVIAN in European countries.

North America to be the Dominating Region

Cancer incidence and prevalence are notably higher in North American countries like the United States and Canada, driving higher demand and contributing to the lead of the North America region in the global companion diagnostics market. The demand for companion diagnostics products in the region is anticipated to grow exponentially due to the high number of cancer cases diagnosed, advanced healthcare services, wide adoption and awareness about companion diagnostics, and increasing affordability of healthcare through government support. Additionally, the United States FDA's significant contribution to product development and regulatory approvals also helps in the market expansion.

For instance, in November 2023, Foundation Medicine Inc. announced the receipt of US FDA approval for FoundationOneCDx as a companion diagnostic solution for AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant). Truqap and Faslodex are already approved by US FDA to treat adult patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, with identified alterations in PIK3CA/AKT1/PTEN genes, after progression on a prior endocrine-based treatment in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.

Future Market Scenario

The future of the global companion diagnostics market holds the development and commercialization of companion diagnostics products that can be used for indications other than oncology such as infectious diseases. Roche's launched the first infectious disease companion diagnostics tests and cobas omni utility channel in December 2021. Since then, several high-quality products have been in the pipeline and there is notable traction of market players for the development of such products.

For instance, Advanta Genetics is aiming to develop products for infectious disease companion diagnostics using precision metagenomics. Another example from the clinical trial repository indicates three companion diagnostics products of Prometheus Biosciences, Inc., which is a subsidiary of Merck & Co., Inc. The company holds three companion diagnostics products in the pipeline for indications other than cancer such as diffuse cutaneous systemic sclerosis, interstitial lung disease, Crohn's disease, and ulcerative colitis.

Key Players Landscape and Outlook

The market players are actively involved in the expansion of their market offerings through strategic product development and approvals, mergers and acquisitions, and collaborations with other key players.

In March 2023, QIAGEN N.V. signed up for a strategic partnership with Servier which is a global pharmaceutical organization, to develop a novel companion diagnostic test called TIBSOVO, containing an isocitrate dehydrogenase-1 (IDH1) inhibitor and indicated for the management of the acute myeloid leukemia. Under the Master Collaboration Agreement, QIAGEN is to develop and validate a real-time in-vitro PCR test that can be used for the detection of IDH1 gene mutations in AML patients using their whole blood and bone marrow aspirates. The experienced regulatory teams of QIAGEN will provide support for clinical validation of the companion diagnostic product and its approval in various geographies including the United States, the EU, and Japan.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Companion Diagnostics Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2.By Product
    • 4.2.1. Assay, Kits and Reagents
    • 4.2.2. Software and Services
  • 4.3.By Technology
    • 4.3.1. Immunohistochemistry
    • 4.3.2. Molecular Diagnostics
    • 4.3.3. In-situ Hybridization
    • 4.3.4. FISH
    • 4.3.5. CISH
    • 4.3.6. Real-time PCR
    • 4.3.7. Gene Sequencing
  • 4.4.By Application
    • 4.4.1. Colorectal Cancer
    • 4.4.2. Breast Cancer
    • 4.4.3. Lung Cancer
    • 4.4.4. Melanoma
    • 4.4.5. Gastric Cancer
    • 4.4.6. Others
  • 4.5.By End-user
    • 4.5.1. Pharmaceutical and Biotechnology Companies
    • 4.5.2. Clinical Research Organizations
    • 4.5.3. Others
  • 4.6.By Region
    • 4.6.1.North America
    • 4.6.2.Europe
    • 4.6.3.Asia-Pacific
    • 4.6.4.South America
    • 4.6.5.Middle East and Africa
  • 4.7.By Company Market Share (%), 2023

5.Global Companion Diagnostics Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2. By Product
      • 5.1.2.1.Assay, Kits and Reagents
      • 5.1.2.2.Software and Services
    • 5.1.3. By Technology
      • 5.1.3.1.Immunohistochemistry
      • 5.1.3.2.Molecular Diagnostics
      • 5.1.3.3.In-situ Hybridization
      • 5.1.3.4.FISH
      • 5.1.3.5.CISH
      • 5.1.3.6.Real-time PCR
      • 5.1.3.7.Gene Sequencing
    • 5.1.4. By Application
      • 5.1.4.1.Colorectal Cancer
      • 5.1.4.2.Breast Cancer
      • 5.1.4.3.Lung Cancer
      • 5.1.4.4.Melanoma
      • 5.1.4.5.Gastric Cancer
      • 5.1.4.6.Others
    • 5.1.5. By End-user
      • 5.1.5.1.Pharmaceutical and Biotechnology Companies
      • 5.1.5.2.Clinical Research Organizations
      • 5.1.5.3.Others
    • 5.1.6. United States*
      • 5.1.6.1.Market Size & Forecast
      • 5.1.6.1.1.By Value
      • 5.1.6.1.2.By Volume
      • 5.1.6.2.By Product
      • 5.1.6.2.1.Assay, Kits and Reagents
      • 5.1.6.2.2.Software and Services
      • 5.1.6.3.By Technology
      • 5.1.6.3.1.Immunohistochemistry
      • 5.1.6.3.2.Molecular Diagnostics
      • 5.1.6.3.3.In-situ Hybridization
      • 5.1.6.3.4.FISH
      • 5.1.6.3.5.CISH
      • 5.1.6.3.6.Real-time PCR
      • 5.1.6.3.7.Gene Sequencing
      • 5.1.6.4.By Application
      • 5.1.6.4.1.Colorectal Cancer
      • 5.1.6.4.2.Breast Cancer
      • 5.1.6.4.3.Lung Cancer
      • 5.1.6.4.4.Melanoma
      • 5.1.6.4.5.Gastric Cancer
      • 5.1.6.4.6.Others
      • 5.1.6.5.By End-user
      • 5.1.6.5.1.Pharmaceutical and Biotechnology Companies
      • 5.1.6.5.2.Clinical Research Organizations
      • 5.1.6.5.3.Others
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3.Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4.South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5.Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6.Market Mapping, 2023

  • 6.1.By Product
  • 6.2.By Technology
  • 6.3.By Application
  • 6.4.By End-user
  • 6.5.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.4.7.Supplier Power
    • 7.4.8.Buyer Power
    • 7.4.9.Substitution Threat
    • 7.4.10.Threat from New Entrant
    • 7.4.11.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Roche Molecular Systems Inc.
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Dako Inc.
  • 13.3.Qiagen Ltd.
  • 13.4.bioMerieux Inc.
  • 13.5.Ventana Medical Systems Inc.
  • 13.6.Abbott Molecular Inc.
  • 13.7.Myriad Genetics Inc.
  • 13.8.Biogenex Laboratories, Inc.
  • 13.9.Thermo Fisher Scientific Inc.
  • 13.10.Leica Biosystems Nussloch GmbH

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 3.Global Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 4.Global Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 5.Global Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 6.Global Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 7.Global Companion Diagnostics Market Share (%), By Region, 2017-2031F
  • Figure 8.North America Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 9.North America Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 10.North America Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 11.North America Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 12.North America Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 13.North America Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 14.North America Companion Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 15.United States Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 16.United States Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 17.United States Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 18.United States Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 19.United States Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 20.United States Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 21.Canada Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 22.Canada Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 23.Canada Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 24.Canada Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 25.Canada Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 26.Canada Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 27.Mexico Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 28.Mexico Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 29.Mexico Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 30.Mexico Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 31.Mexico Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 32.Mexico Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 34.Europe Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 35.Europe Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 36.Europe Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 37.Europe Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 38.Europe Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 39.Europe Companion Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 40.Germany Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 41.Germany Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 42.Germany Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 43.Germany Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 44.Germany Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 45.Germany Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 46.France Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.France Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 48.France Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 49.France Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 50.France Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 51.France Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 52.Italy Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 53.Italy Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 54.Italy Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 55.Italy Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 56.Italy Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 57.Italy Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 58.United Kingdom Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 59.United Kingdom Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 60.United Kingdom Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 61.United Kingdom Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 62.United Kingdom Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 63.United Kingdom Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 64.Russia Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 65.Russia Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 66.Russia Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 67.Russia Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 68.Russia Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 69.Russia Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 70.Netherlands Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 71.Netherlands Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 72.Netherlands Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 73.Netherlands Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 74.Netherlands Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 75.Netherlands Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 76.Spain Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 77.Spain Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 78.Spain Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 79.Spain Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 80.Spain Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 81.Spain Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 82.Turkey Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 83.Turkey Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 84.Turkey Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 85.Turkey Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 86.Turkey Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 87.Turkey Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 88.Poland Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Poland Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 90.Poland Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 91.Poland Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 92.Poland Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 93.Poland Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 94.South America Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 95.South America Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 96.South America Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 97.South America Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 98.South America Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 99.South America Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 100.South America Companion Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 101.Brazil Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 102.Brazil Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 103.Brazil Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 104.Brazil Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 105.Brazil Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 106.Brazil Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 107.Argentina Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 108.Argentina Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 109.Argentina Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 110.Argentina Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 111.Argentina Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 112.Argentina Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 113.Asia-Pacific Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 114.Asia-Pacific Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 115.Asia-Pacific Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 116.Asia-Pacific Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 117.Asia-Pacific Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 118.Asia-Pacific Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 119.Asia-Pacific Companion Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 120.India Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 121.India Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 122.India Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 123.India Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 124.India Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 125.India Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 126.China Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 127.China Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 128.China Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 129.China Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 130.China Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 131.China Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 132.Japan Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 133.Japan Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 134.Japan Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 135.Japan Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 136.Japan Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 137.Japan Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 138.Australia Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 139.Australia Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 140.Australia Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 141.Australia Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 142.Australia Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 143.Australia Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 144.Vietnam Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 145.Vietnam Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 146.Vietnam Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 147.Vietnam Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 148.Vietnam Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 149.Vietnam Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 150.South Korea Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 151.South Korea Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 152.South Korea Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 153.South Korea Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 154.South Korea Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 155.South Korea Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 156.Indonesia Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 157.Indonesia Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 158.Indonesia Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 159.Indonesia Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 160.Indonesia Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 161.Indonesia Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 162.Philippines Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 163.Philippines Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 164.Philippines Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 165.Philippines Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 166.Philippines Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 167.Philippines Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 168.Middle East & Africa Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 169.Middle East & Africa Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 170.Middle East & Africa Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 171.Middle East & Africa Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 172.Middle East & Africa Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 173.Middle East & Africa Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 174.Middle East & Africa Companion Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 175.Saudi Arabia Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 176.Saudi Arabia Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 177.Saudi Arabia Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 178.Saudi Arabia Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 179.Saudi Arabia Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 180.Saudi Arabia Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 181.UAE Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.UAE Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 183.UAE Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 184.UAE Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 185.UAE Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 186.UAE Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 187.South Africa Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 188.South Africa Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
  • Figure 189.South Africa Companion Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 190.South Africa Companion Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 191.South Africa Companion Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 192.South Africa Companion Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 193.By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194.By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195.By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023